Irish AI-based health platform Cambrean has been acquired by US health technology company Nucleus for an undisclosed sum.
As part of the deal, Cambrean founder David Sloane will join NUcleus, and relocate to New York to work with the company. The company’s chief medical officer is taking on an advisory role with Nucleus.
The value of the deal was not disclosed.
Cambrean’s technology turns data from wearable devices into actionable health insights, and will form part of Nucleus’s plans to integrate the real-time data with genetic insights to monitor health and help manage the risk of future or chronic illness.
Zuckerberg’s culture shift at Meta could make it hard to find new recruits willing to work in his macho organisation
Keeping sea lice from farmed fish will boost aquaculture health and profits
Bosch Unlimited 7 Aqua review: Saving time and effort on household cleaning
Irish space race: domestic companies pushing the frontiers of AI, space stations and acoustic technology
“Thoughtfully integrating each data point with DNA is the way to tell the complete story about someone’s health. That’s what we plan on doing with Cambrean,” said Kian Sadeghi, founder and CEO of Nucleus.
“We’re reimagining healthcare by building a data-rich, AI-driven ecosystem that begins with genetic insights and extends to every aspect of personal health management.”
Cambrean is the brainchild of Mr Sloane, who founded the company more than three years ago. Among its supporters is entrepreneur Dan Kiely.
Mr Sloane described the company’s technology, which combines data on sleep, nutrition, workouts, activities and vitals from multiple data sources such as Apple Watch or Oura rings in one analysis, as similar to an Apple Health app, but with better insights.
“There’s a lot of data that we’re already collecting, and we just wanted to be better at actually analysing that data and utilising and getting the most that we could from it,” he said.
A pre-existing relationship with Mr Sadeghi helped pave the way for the deal, with Mr Sloane saying the two companies shared a similar vision for the future of healthcare.
The acquisition comes after Nucleus closed its $14 million Series A round, bringing the company’s total funding to nearly $32 million. The round includes new funding from Neo, Giant Step Capital, One Eight Capital, and angel investors such as Balaji Srinivasan and Achal Upadhyaya.
- Sign up for the Business Today newsletter and get the latest business news and commentary in your inbox every weekday morning
- Opt in to Business push alerts and have the best news, analysis and comment delivered directly to your phone
- Join The Irish Times on WhatsApp and stay up to date
- Our Inside Business podcast is published weekly – Find the latest episode here
